PartnershipJun 24, 2026, 08:32 AM
LENZ Therapeutics Partners with Arrotex for VIZZ in Australia/NZ
AI Summary
LENZ Therapeutics, Inc. announced an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. for VIZZ, its FDA-approved presbyopia treatment, in Australia and New Zealand. Under the terms, LENZ will receive an upfront payment and a significant profit share from gross margin, while Arrotex gains exclusive commercialization rights. This partnership marks LENZ's fifth ex-US commercialization deal for VIZZ, expanding its global reach for the innovative eye drop.
Key Highlights
- LENZ Therapeutics and Arrotex Pharmaceuticals signed an exclusive license and commercialization agreement.
- Arrotex will register and commercialize VIZZ for presbyopia in Australia and New Zealand.
- LENZ will receive an upfront payment and a significant profit share of gross margin from sales.
- Arrotex obtains exclusive commercialization rights for VIZZ in Australia and New Zealand.
- This is LENZ's fifth ex-US commercialization partnership for VIZZ.
- VIZZ (aceclidine ophthalmic solution) 1.44% is the first and only FDA-approved aceclidine-based eye drop.
- VIZZ was approved by the FDA in July 2025 and commercially available in the US since October 2025.
- VIZZ is a once-daily eye drop designed to restore clear near vision for up to 10 hours.
Price Impact
More from LENZ